Increasing Adenovirus Upstream Process Productivity Using a High Cell Density Perfusion Strategy
Biotechnology and Bioengineering · 18.11.2026
DOI: 10.1002/bit.70443 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biotechnology and Bioengineering, online erschienen am 18.11.2026. Verfasst von Alena Roßkamp und 11 weiteren Autor:innen. Beteiligte Einrichtung: Sartorius Stedim Biotech GmbH, Goettingen, Germany. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sartorius Stedim Biotech GmbH, Engineering and Physical Sciences Research Council Manufacturing Research Hub for a Sustainable Future (VaxHub Sustainable), UK Department of Health and Social Care VaxHub Global project.
Abstract (Originalsprache)
Adenovirus vectors are a major vaccine platform and have potential roles as oncolytics and gene therapies. Large‐scale production of adenovirus‐vectored COVID‐19 vaccines demonstrated the value of platform manufacturing processes for such products but vaccine scarcity remained problematic in 2021. There is a need for widely‐accessible and higher‐yielding platform processes for adenovirus production. Such processes must overcome cell‐density‐associated productivity limitation and the potential impact of vector transgene expression. We report a process capable of upstream productivity of 3 ×10 12 virus particles per mL, solely using commercially‐accessible materials. This combines perfusion cell culture with a highly‐productive cell line capable of vector transgene repression. Using a multi‐parallel scaledown perfusion bioreactor system, we selected straightforward perfusion conditions for both expansion of uninfected cells and virus production. This achieves maintenance of high cell‐specific productivity at cell densities up to 40 ×10 6 cells per mL. We believe this may be the highest productivity yet reported for an adenovirus platform, including previous reports using proprietary cell lines. This highly productive process could be valuable both in large‐scale production and in maximizing the output of smaller facilities making products for niche indications or stockpiles.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Sartorius Stedim Biotech GmbH, Goettingen, Germany.
- Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
ORCID-Profile: Julia Talarek, Faith Vinluan, Alexander D Douglas
Förderung
- Sartorius Stedim Biotech GmbH
- Engineering and Physical Sciences Research Council Manufacturing Research Hub for a Sustainable Future (VaxHub Sustainable)
- UK Department of Health and Social Care VaxHub Global project
- Wellcome
Zitieren
APA
Roßkamp, A., Vieira, J., Hussain, S., Talarek, J., Vinluan, F., Joe, C. C. D., Scholze, S., Speckenbach, M., Madarasi-Pap, P., Kueppers, S., Niemann, J., & Douglas, A. D. (2026). Increasing Adenovirus Upstream Process Productivity Using a High Cell Density Perfusion Strategy. Biotechnology and Bioengineering. https://doi.org/10.1002/bit.70443
Vancouver
Roßkamp A, Vieira J, Hussain S, Talarek J, Vinluan F, Joe CCD, et al. Increasing Adenovirus Upstream Process Productivity Using a High Cell Density Perfusion Strategy. Biotechnology and Bioengineering. 2026. doi:10.1002/bit.70443
BibTeX
@article{Rokamp2026,
author = {Roßkamp, Alena and Vieira, Jacqueline and Hussain, Shawkat and Talarek, Julia and Vinluan, Faith and Joe, Carina C D and Scholze, Steffi and Speckenbach, Moritz and Madarasi-Pap, Paul and Kueppers, Sophia and Niemann, Julia and Douglas, Alexander D},
title = {Increasing Adenovirus Upstream Process Productivity Using a High Cell Density Perfusion Strategy},
journal = {Biotechnology and Bioengineering},
year = {2026},
doi = {10.1002/bit.70443}
}
EUVIMED